Next Article in Journal
Content of Phenolic Compounds in Meadow Vegetation and Soil Depending on the Isolation Method
Next Article in Special Issue
Identifying Terpenoid Biosynthesis Genes in Euphorbia maculata via Full-Length cDNA Sequencing
Previous Article in Journal
(E)-1-(Furan-2-yl)-(substituted phenyl)prop-2-en-1-one Derivatives as Tyrosinase Inhibitors and Melanogenesis Inhibition: An In Vitro and In Silico Study
Previous Article in Special Issue
Tert-butyl-(4-hydroxy-3-((3-(2-methylpiperidin-yl)propyl)carbamoyl)phenyl)carbamate Has Moderated Protective Activity in Astrocytes Stimulated with Amyloid Beta 1-42 and in a Scopolamine Model
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 25
Issue 22
10.3390/molecules25225461
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis of Polycyclic Ether-Benzopyrans and In Vitro Inhibitory Activity against Leishmania tarentolae

by
Sarita Singh
,
Jacob P. Grabowski
,
Shilpa Pohani
,
C. Fiore Apuzzo
,
David C. Platt
,
Marjorie A. Jones
* and
T. Andrew Mitchell
*
Department of Chemistry, Illinois State University, Campus Box 4160, Normal, IL 61790-4160, USA
*
Authors to whom correspondence should be addressed.
Molecules 2020, 25(22), 5461; https://doi.org/10.3390/molecules25225461
Submission received: 26 October 2020 / Revised: 14 November 2020 / Accepted: 18 November 2020 / Published: 21 November 2020
(This article belongs to the Special Issue Organic Synthesis in Natural Products and Bioactive Compounds)
Browse Figures
Versions Notes

Abstract

:
Construction of a focused library of polycyclic ether-benzopyrans was undertaken in order to discover new therapeutic compounds that affect Leishmania growth and infectivity. This is especially of interest since there are few drug therapies for leishmaniasis that do not have serious drawbacks such high cost, side effects, and emerging drug resistance. The construction of these polycyclic ether-benzopyrans utilized an acetoxypyranone-alkene [5+2] cycloaddition and the Suzuki-Miyaura cross-coupling. The multi-gram quantity of the requisite aryl bromide was obtained followed by effective Pd-catalyzed coupling with boronic acid derivatives. Compounds were tested in vitro using the parasitic protozoan, Leishmania tarentolae. Effects of concentration, time, and exposure to light were evaluated. In addition, the effects on secreted acid phosphatase activity and nitric oxide production were investigated, since both have been implicated in parasite infectivity. The data presented herein are indicative of disruption of the Leishmania tarentolae and thus provide impetus for the development and testing of a more extensive library.

1. Introduction

According to the Centers for Disease Control and Prevention (CDC), leishmaniasis is a neglected tropical disease caused by parasitic protozoans in the genus Leishmania [1] that affects humans and animals in nearly 100 countries [2] with cases reported on every continent except Australia and Antarctica [3]. The exact number of leishmaniasis cases is not known but is reported to be between 1.5 and 2.0 million new cases per year with more than 350 million people at risk worldwide [4]. Although less common in the United States than many other parts of the western hemisphere [5], cases of cutaneous leishmaniasis have been documented in Oklahoma and Texas [6,7], raising concerns that this neglected disease will become a US public health issue sooner rather than later [8]. Leishmaniasis is caused by 20 different species of Leishmania and is spread by the bite of approximately 30 different species of phlebotomine sandflies [2]. Leishmaniasis is presented clinically in three different forms: cutaneous, visceral, or mucosal [2,9]. Although several treatments exist, they are not without liabilities [10,11]. For example, amphotericin B is cost-prohibitive, antimony compounds are toxic, and both therapies have significant side-effects. There are three main modes of therapy, including systemic parenteral, systemic oral, and local (i.e., topical application). Examples of systemic parenteral therapies include various drug formulations of pentavalent antimony (Sb+5) compounds. Systemic oral therapy may include the phosphocholine derivative miltefosine or a triazole-containing small molecule such as fluconazole. Examples of local therapies range from cryotherapy with liquid nitrogen to thermotherapy with localized current field radiofrequency heat, in addition to the intralesional administration of antimony-based compounds or topical application of paromomycin [12]. These treatments can be expensive and may result in harsh side effects with reports of drug resistance becoming a serious problem, so there is a critical need for new drugs to treat this neglected tropical disease [1,2]. Recently, a polycyclic ether-containing natural product, englerin A, was reported to be toxic in renal cancer cells and has become a very popular synthetic target (Figure 1) [13,14,15,16]. One hypothesis regarding the mechanism of action is a complex array of metabolic pathways involving PKCθ and HSF1, leading to an inhibition of glucose transporter (Glut1) activity [17]. In addition, Feng et al. reported that glucose transporters are critical for Leishmania mexicana viability and infectivity [18]. Furthermore, benzopyrans [19,20,21] are classified as privileged structures toward medicinal chemistry efforts [22] and benzopyran-chalcones have been shown to inhibit Leishmania major [23,24]. Thus, we hypothesized that hybrid oxabicyclo[3.2.1]-octane-benzopyrans 1 offered a unique scaffold to pursue inhibitory activity against the protozoan parasite Leishmania tarentolae [25]. This strain of Leishmania is generally regarded as non-pathogenic to humans, and it therefore serves as a model system in vitro [26]. We observed that these compounds negatively affect parasite growth and viability in vitro with mechanistic targets such as nitric oxide production and secreted acid phosphatase activity, both of which are proposed to be involved in parasite-host interactions [27,28]. We also included tests against mammalian glial cells, in culture, to evaluate toxicity for another cell type.
In addition to the total synthesis of natural products [29,30,31,32,33,34,35,36], there is constant demand for the synthesis of unnatural heterocycles to access novel chemical space [37,38,39,40,41,42,43,44,45]. Although not authentic derivatives of secondary metabolites, these moieties resemble inherently diverse natural products [46,47,48,49,50,51,52]. Using natural products as metaphorical lead compounds, important heterocyclic scaffolds have been developed that would have otherwise remained undiscovered. Toward this end, cycloadditions provide an efficient means to synthesize valuable three-dimensional rings [53,54,55]. For example, Diels–Alder [4+2] cycloadditions are ubiquitous among organic reactions [56,57,58], while [5+2] cycloadditions are substantially less recognized [59,60]. However, polycyclic ethers are very important heterocyclic ring systems [61], and oxidopyrylium-based [5+2] cycloadditions (Figure 2) afford valuable oxabicyclo[3.2.1]-octanes [62,63,64] which are embedded within such natural products [65,66,67,68,69,70] as englerin A [13,14,15,16], platensimycin [71,72], cortistatins [73,74], and many others [75,76,77].

2. Results and Discussion

2.1. Previous Synthesis of Polycyclic Ether-Benzopyran

As part of our research program directed toward [5+2] cycloadditions [78,79,80,81,82,83,84] we explored mechanistic pathways of acetoxypyranone-derived oxidopyrylium species en route to [5+2] cycloadditions [81] that led to the discovery of polycyclic ether-benzopyran 4 (Scheme 1). Commercially available aldehyde 2 was treated with 2-furyllithium to provide the desired alcohol (not shown) in quantitative yield. Achmatowicz rearrangement [85,86,87,88] followed by acylation afforded the acetoxypyranone 2 as a mixture of diastereomers in 41% yield over three steps. Finally, N-methylpyrrolidine (NMP)-mediated [5+2] cycloaddition [83] delivered the ether-benzopyran 4 in 83% yield.

2.2. Proposed Suzuki-Miyaura Pathway toward Construction of Ether-Benzopyran Analogues

Toward construction of a library of polycyclic ether-benzopyran analogues 1, we envisioned the synthesis of aryl bromide 6 that would be suitable for Suzuki cross-coupling [89,90] with biologically relevant [91] boronic acid derivatives 5 (Scheme 2). The alcohol 6 would be accessible via Luche reduction [92] of enone 7, which would arise from the key [5+2] cycloaddition. The cycloadduct 7 would be accessible by the aforementioned sequence (cf. Scheme 1) utilizing aryl bromide 8, which is readily accessible upon the allylation of commercially available 5-bromo-salicyladehyde (not shown).

2.3. Construction of the Suzuki-Miyaura Aryl Bromide Precursor

En route to cross-coupling partner 6, commercially available 5-bromosalicylaldehyde 9 was heated in acetonitrile with allyl bromide and K2CO3 to give allyl ether 8 in 97% yield (Scheme 3). The treatment of furan with nBuLi in THF provided the 2-furyllithium, which underwent addition to aldehyde 8 to afford the alcohol 10. Next, mCBPA-mediated Achmatowicz rearrangement [85,86,87,88] delivered the hydroxypyranone (not shown), which was acylated to give the acetoxypyranone 11 in 71% yield over two steps. NMP was utilized to promote the [5+2] cycloaddition [83] to afford the ketone 7 in 95% yield as a single diastereomer. Luche reduction [92] gave the allylic alcohol 6, which was included to provide a hydrogen-bond donor and remove the reactive enone functionality [93].

2.4. Palladium Catalyzed Suzuki-Miyaura Cross-Coupling

Suzuki-Miyaura cross-coupling [89,90] is one of the most widely used reactions to construct C-C bonds and affords an effective delivery of relevant heterocycles [91]. Aryl bromide 6 provides the necessary functional group handle to react with boronic acid derivatives 5a–e with catalytic palladium to deliver products 1a–e (Table 1). In general, Pd(Ph3)4 was utilized as the catalyst with Cs2CO3 in a mixed solvent system of toluene, DME, and water to afford the desired cross-coupling products 1a,c–e (entries 1, 3–5). However, in the case of 2-fluoropyridine-4-boronic acid 5b (entry 2), Pd(dppf)Cl2 and K2CO3 in toluene:EtOH provided the desired product 1b [94]. In all cases, the starting material 6 was consumed according to 1H NMR analyses of the crude reaction mixtures.

2.5. Biological Investigations

2.5.1. Incubation Effects on L. tarentolae Growth

No major differences were observed via light microscopy (data not shown) in the morphology or motility of L. tarentolae following 96-h incubations. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) viability assay [95] was used to evaluate cell viability with and without the test compounds. Initial MTT values were essentially the same, suggesting that the same number of viable cells were present in each of the separate flasks prior to the addition of the polycyclic ether-benzopyrans. Subsequent MTT values were altered in the presence of some of the test compounds in comparison to the DMSO control (Figure 3) and this is especially evident on day 2 post addition of the 1e compound. On day 1 post addition of compounds 1a,1c, 1d, and 1e, values were significantly different (p, 0.05) from DMSO control cells. One day 2, all additions resulted in significant differences relative to DMSO control cells. On day 3, all additions resulted in significant differences except compound 1d. On day 4, all additions resulted in significant differences except compound 1a. It is of interest that compound 1e has an apparent early inhibitory effect on cells, relative to control cells, but that, with time, the compound is not stable, so the inhibition is relieved, and the cells recover.

2.5.2. Test Compound Inhibition and Apparent Recovery by Leishmania after Transfer to New Medium

Inhibition of L. tarentolae growth was seen by several compounds (Figure 4) with the most effective inhibitory compounds being compound 1c and co-incubation of compounds 1c + 1e. Slopes obtained for the original growth period and the secondary recovery phase indicate some level of recovering capabilities after exposure to different compounds (Table 2), since a greater ratio of the slope corresponds to an increased ability to recover after compound exposure. For all days post addition of compounds 1a, 1c, 1d, and co-incubation with 1c + 1e, there was a statistically significant change relative to control cells (p < 0.05).
Significant differences were observed in the differential growth patterns of experimental cultures compared to DMSO control. Complexes appear to be affecting various pathways involved in cell maturation and division. Growth curve plots show severe growth inhibition in the presence of multiple compounds. Although indole 1c shows the highest inhibitory activity, this compound also reveals synergistic activity in the presence of pyrimidine 1e. The difference in recovery is minimal between each sample when comparing the ratio of the slopes. No condition appeared to bring the cellular viability to 0. However, this was a one-dose study (addition at 0 h) and it is likely that a multidose study would further affect the cellular viability of the parasite.

2.5.3. Incubation Effects of Secreted Acid Phosphatase (SAP) Activity

Secreted acid phosphatase (SAP) activity on the fourth day (96 h post-addition) showed a marked difference between control and experimental conditions (Figure 5). Normalizing the absorbance obtained for SAP activity to the day 4 MTT absorbance suggests that SAP activity is directly or indirectly affected in the presence of the test compounds (Figure 6). For all compounds tested, there was a significant increase (p < 0.05) in secreted acid phosphatase activity relative to DMSO control cells.

2.5.4. Standard SAP Direct Enzymic Effect Assay

A 15-min pre-incubation period before substrate addition showed a decrease in SAP activity with compounds 1b and 1e being the most effective (Figure 7). The 18-h and 46-h pre-incubation periods showed little difference to control in terms of SAP activity, suggesting that enzymatic inhibition may have occurred during the 15-min pre-incubation period, resulting in a lower enzyme activity and less product formed. However, with time, the enzyme activity appears to recover, suggesting that the test compounds may not be stable under these incubation conditions.

2.5.5. Standard Leishmania SAP Enzyme Kinetic Assay

A 15-min pre-incubation period was allotted for the enzyme to interact with each test compound before starting the enzymatic reaction with the addition of substrate. V vs. [S] curves between conditions show no difference in enzyme activity depending on either test compound present or substrate concentration. Lineweaver-Burk plots for each condition yield very similar KM and Vmax values, suggesting no direct modulation as either an activator or inhibitor of Leishmania SAP activity (Table 3).
In all cases (cf. Figure 5), the detectable SAP activity was similar to or larger than the DMSO control cells, suggesting some effect on either the cells’ ability to synthesize or release this important parasite enzyme. It was of interest that incubation with compound 1d resulted in the highest value of detectable SAP activity. When normalizing the absorbance obtained for SAP activity to the day 4 MTT absorbance, it appears that the SAP activity is directly or indirectly affected in the presence of the test compounds (Figure 6). Comparable values for both KM and Vmax for all conditions (Table 3) suggests no direct enzymic effect of activation or inhibition on SAP by 6, 1c, and 1d. These data suggest that some test compounds affect the Leishmania cells’ ability to synthesize or release the secreted acid phosphatase (SAP) enzyme, but do not directly affect the enzyme activity.

2.5.6. Detection of Leishmania Nitric Oxide Using a Specific Fluorescent Probe, DAF-FM

Aliquots (equal volumes from each condition) of cells were centrifuged, resuspended and incubated, washed, and plated for microscopy. All compounds showed a modest decrease in NO production relative to the 1% DMSO control (Table 4). However, 1b, 1e, and co-incubation with 1b + 1e show a more substantial decrease in NO levels than the other compounds. These trends are shown in the microscope images (Figures S15–S20) at 40x magnification in which green indicates cells responding to the probe for nitric oxide. Note that there were no observable differences in cell morphology when comparing control (with DMSO) to experimental cells. This is of interest since the production of nitric oxide by Leishmania has been proposed as one mechanism by which these parasites protect themselves from oxidative stress [27]. Then a reduction in nitric oxide production may render these parasites less infective to host cells. Further studies should be conducted using standard inducible nitric oxide synthase (iNOS) to test if either of these two compounds acts as a direct enzyme inhibitor.

2.5.7. Cell Toxicity Screening: C6 Glial Cells

No acute toxicity was seen in glial cells following a 2-h incubation with the various test compounds relative to DMSO control (Table 5). In contrast to the viability assays with L tarentolae, our investigations of all test compounds were not found to be acutely toxic to glial cells in vitro. This suggests that these compounds may not be as hazardous to mammalian cells. Short term incubation, with other compounds, has been shown previously to elicit acute cytotoxicity in glial cells [96]. A therapeutic use of these compounds targeted toward inhibiting Leishmania based infection should be further investigated.

2.5.8. ED-50 (Effective Dose) Study on Leishmania

The toxicity assay was replicative of earlier incubation results, suggesting no toxicity from 6, and a cytotoxic effect from 1c and 1e. The formation of a trendline was used on the linear portion for both 1c and 1e to estimate an ED-50 concentration for both days after addition (Table 6). Compound 6 had no apparent effect on the cell viability at levels up to 200 µM.
Compounds 1c and 1e clearly show some level of toxicity to L. tarentolae, whereas 6 does not. The second day MTT measurement of 1c incubated L. tarentolae decreased from the first day suggesting that the L. tarentolae may be unable to recover from exposure, especially at higher concentrations. This ability to recover is seen at lower (less than 40 µM) but not higher concentrations with 1e, as shown in Figure 8.

2.5.9. Photosensitivity study on Leishmania

No difference in light exposure sensitivity was seen immediately after uptake period and light exposure between experimental and control cultures (Table 7). However, by 24 h, cells with test compound 1c exhibited a reduction in cell viability but independent of light treatment. In contrast, 1e or 6 treated cells exhibited no toxicity throughout the entire trial under any light condition. In general, L. tarentolae appeared to be resistant to exposure to both UV and fluorescent light under these experimental conditions. Compound 1e MTT levels are in line with DMSO control, which was unexpected, as all other studies showed some level of toxicity. One possible explanation is that this molecule is not as stable as the others and thus stock preparations undergoing multiple freeze-thaw cycles in DMSO from −20 °C to tepid water rendered this inactive. Compound 1c continued to exhibit the same toxic effect to L. tarentolae, as it was not dependent on the light exposure received implying that light exposure has no effect on uptake and/or toxicity of 1c.

3. Conclusions

Due to the pressing need for new small molecules to treat Leishmaniasis, hybrid polycyclic ether-benzopyrans were constructed in order to combine the potential glucose transporter inhibition with the privileged benzopyran structure. The construction of this new scaffold was undertaken by utilizing the complexity-generating [5+2] cycloaddition in conjunction with the Suzuki-Miyaura cross-coupling to deliver biologically relevant heterocycles. Leishmania tarentolae growth was shown to be affected in the presence of these organic molecules to differing extents with no noticeable change in cell morphology, motility, or clumping. Although the biochemical mechanisms are not fully understood, two different enzymes were evaluated in this study, namely secreted acid phosphatase and (indirectly) nitric oxide synthase. SAP secretion or transcriptional regulation may be affected by the presence of these polycyclic ether-benzopyrans, since we found that there is differing MTT normalized SAP readings from in vitro incubation. However, none of the compounds tested appear to have a direct, modulatory effect on SAP as an activator or inhibitor. The reduction in detectable nitric oxide by some of the test compounds was substantial and may reduce the ability of these cells to detoxify reactive oxygen species of host cells. Acute toxicity does not seem to occur in cultured glial cells indicating a differential effect relative to cell type. Polycyclic ether-benzopyrans 1c and 1e appear to have the most inhibitory effects on Leishmania tarentolae viability through a concentration and time-dependent manner. Exposure to different wavelengths of light does not seem to affect toxicity levels of these two complexes. Under some conditions, the compounds do not appear to be stable with time, suggesting that potential therapy will involve multiple dosing to bring about successful reduction of the parasitic load. Future work will focus on evaluation of the mechanism of action especially involving the GLUT transporter by which these polycyclic ether-benzopyrans affect Leishmania in vitro.

4. Materials and Methods

4.1. General Methods—Organic Synthesis

All reactions were performed under Ar atmosphere in oven-dried or flame-dried glassware unless otherwise noted. Diethyl ether (Et2O) was dried over pressed Na metal. All other commercially available anhydrous solvents and reagents were used as received. Sodium hydride (NaH) was a 60% dispersion in mineral oil. Thin layer chromatography was performed with glass or aluminum plates (silica gel F254, Art 5715, 0.25 mm), visualized by fluorescence quenching under UV light, and stained with potassium permanganate. Flash column chromatography (FCC) was performed with silica gel 60A 40–63 µm (200–400 mesh). Mass spectral data were acquired using positive mode Electrospray Ionization (ESI+) and a high-resolution Time of Flight (TOF) mass spectrometer (ThermoFisher Scientific, Waltham, MA, USA). 1H NMR spectra were acquired at 400 or 500 MHz and 13C{1H} NMR spectra were acquired at 100 MHz or 125 MHz as noted (Bruker, Billerica, MA, USA). 1H and 13C{1H} NMR chemical shifts are reported in ppm (δ) relative to the residual solvent peaks. 1H NMR coupling constants (J) are reported in Hertz (Hz), and multiplicities are indicated as follows: s (singlet), br. s (broad singlet), d (doublet), t (triplet), q (quartet), quint (quintet), sext (sextet), sept (septet), dd (doublet of doublets), ddd (doublet of doublet of doublets), dt (doublet of triplets), td (triplet of doublets), ddt (doublet of doublet of triplets), dq (doublet of quartets), qq (quartet of quartets), ovlp (overlapping), m (multiplet), app. (apparent). Based on intensity in the 13C{1H} spectra, both magnetic and chemical shift equivalent peaks are noted in parentheses. Compounds 6 and 1a-1e were solubilized with DMSO to 30 mM for stock concentration (stored at −20 °C).

4.2. Preparation of Aryl Bromide 6

Aryl bromide 6: To a solution of phenol 9 (10.0 g, 49.7 mmol, 1.0 equiv) in CH3CN (100 mL) was added K2CO3 (10.30 g, 74.58 mmol, 1.5 equiv). Then allyl bromide was delivered to this solution dropwise via syringe. The reaction flask was fitted with an air reflux condenser and stirred for 2.5 h at 60 °C. Then, the reaction was cooled to room temperature and quenched by the addition of water (100 mL). Extraction with ethyl acetate (2 × 100 mL) afforded an organic layer that was washed with 1M NaOH (100 mL) and brine (100 mL), dried with MgSO4, filtered, and concentrated. Crude allyl ether 8 was filtered through a plug of silica with diethyl ether and carried on without further purification (11.72 g, 48.5 mmol, 97%). To a solution of furan (1.40 mL, 19.9 mmol, 1.0 equiv) in THF (15 mL) cooled to −78 °C was added nBuLi (9 mL, 23.8 mmol, 1.2 equiv) dropwise via syringe. The reaction was stirred for 1.5-h at –78 °C, and then warmed to 0 °C for 30 min. Upon cooling back to –78 °C, aldehyde 8 (9.6 g, 39.8 mmol, 2.0 equiv) in THF (45 mL) was added dropwise via syringe. The reaction was stirred for 1-h at –78 °C followed by 30 min at 23 °C. The reaction was quenched by the slow addition of water (100 mL) at 0 °C and extracted with Et2O (300 mL). The combined organic layer was washed with sat. aq. NaCl (100 mL), dried with MgSO4, filtered, and concentrated. Purification by FCC (hexanes:ethyl acetate 90:10) afforded furfuryl alcohol 10 as a yellow solid (2.5 g, 8.1 mmol, 41%). To a solution of furfuryl alcohol 10 (8.0 g, 26.0 mmol, 1.0 equiv) in CH2Cl2 (200 mL) was added mCPBA (8.32 g, 33.75 mmol, 1.3 equiv) at 0 °C. Then, the reaction mixture was stirred for 5 h at 23 °C and quenched by the addition of sat. aq. Na2S2O3 (50 mL), sat. aq. NaHCO3 (50 mL), and 10% aq. Na2CO3 (50 mL). The resulting mixture was extracted with CH2Cl2 (200 mL), dried with Na2SO4, filtered, and concentrated. Purification by FCC (CH2Cl2:Et2O 95:5) afforded hydroxypyranone (not shown) as a white solid (6.09 g, 18.7 mmol, 72%, dr 3:1). To a solution of hydroxypyranone (6.09 g, 18.7 mmol, 1.0 equiv) in CH2Cl2 (150 mL) was added pyridine (3.77 mL, 46.8 mmol, 2.5 equiv) and AcCl (2.0 mL, 28.1 mmol, 1.5 equiv) at 0 °C. The reaction was stirred for 2 h, quenched with sat. aq. NaCl (100 mL), and then separated. The aqueous layer was extracted with CH2Cl2 (200 mL), and the organic layer was dried with Na2SO4, filtered, and concentrated. Purification by FCC (CH2Cl2:Et2O 95:5) afforded acetoxypyranone 11 as a pale yellow solid (6.74 g, 18.4 mmol, 98%). To a solution of acetoxypyranone 11 (6.7 g, 18.4 mmol, 1.0 equiv) in CH3CN (120 mL) was added NMP (7.64 mL, 73.4 mmol, 4.0 equiv). The reaction was heated to 60 °C for 18 h and concentrated. Purification by FCC (CH2Cl2:Et2O 95:5) afforded enone 7 as a white solid (5.38 g, 17.5 mmol, 95%, dr > 19:1): Rf = 0.74 (CH2Cl2:Et2O 85:15); mp 184 °C; 1H NMR (500 MHz, CDCl3) δ 7.41 (dd, J = 9.9, 4.6 Hz, 1H), 7.39–7.35 (m, 2H), 6.90-6.86 (m, 1H), 6.17 (d, J = 9.9 Hz, 1H), 4.88 (app dd, J = 7.1, 4.6 Hz, 1H), 4.42 (dd, J = 10.9, 5.8 Hz, 1H), 3.45 (dd, J = 12.1, 10.9 Hz, 1H), 2.58–2.51 (m, 1H), 2.24 (ddd, J = 12.3, 8.4, 0.6 Hz, 1H), 1.86 (ddd, J = 12.3, 7.1, 4.6 Hz, 1H); 13C{1H} NMR (100 MHz, CDCl3) δ 196.0, 155.6, 153.6, 133.3, 133.0, 127.2, 122.3, 119.3, 113.9, 85.1, 72.5, 68.1, 36.4, 33.6; ESI-HRMS calculated for C14H11BrO3Na [M + Na]+ 328.9789 (Br79) and 330.9769 (Br81), found 328.9784 and 330.9760. To a solution of enone 7 (5.38 g, 17.5 mmol, 1.0 equiv) in CH2Cl2:MeOH (30 mL:120 mL) was added CeCl3•7H2O (13.06 g, 35.0 mmol, 2.0 equiv) at 23 °C. Upon stirring for 30 min, the reaction was cooled to 0 °C and NaBH4 (500 mg, 13.14 mmol, 0.75 equiv) was added slowly. Upon stirring for 30 min at 0 °C, a second portion of NaBH4 (500 mg, 13.14 mmol, 0.75 equiv) was added slowly. The reaction was stirred at 0 °C for 1 h and was quenched via slow addition of sat. aq. NaCl (100 mL). This biphasic solution was diluted with Et2O (200 mL) and separated. The combined organic layer was dried with Na2SO4, filtered, and concentrated. Purification by FCC (CH2Cl2:Et2O 95:5) afforded aryl bromide 6 as a white solid (4.79 g, 15.5 mmol, 88%): Rf = 0.63 (CH2Cl2:Et2O 85:15); mp 133–134 °C; 1H NMR (500 MHz, CDCl3) 1H NMR (500 MHz, CDCl3) δ 7.69 (d, J = 2.4 Hz, 1H), 7.32 (dd, J = 8.7, 2.4 Hz, 1H), 6.86 (d, J = 8.7 Hz, 1H), 6.09 (ddd, J = 9.8, 4.1, 1.8 Hz, 1H), 5.65 (dd, J = 9.8, 2.1 Hz, 1H), 4.77–4.73 (m, 1H), 4.55 (dd, J = 6.0, 4.1 Hz, 1H), 4.37 (dd, J = 9.9, 5.4 Hz, 1H), 3.34 (dd, J = 12.3, 9.9 Hz, 1H), 3.34–3.24 (m, 1H), 2.18 (dd, J = 11.6, 7.8 Hz, 1H), 1.62–1.57 (m, 1H), 1.38 (d, J = 4.7 Hz, 1H); 13C{1H} NMR (125 MHz, CDCl3) δ 156.4, 133.6, 132.3, 131.0, 127.7, 127.1, 119.3, 114.5, 80.4, 74.7, 73.5, 69.9, 36.5, 34.4; ESI-HRMS calculated for C14H13BrO3Na [M + Na]+ 330.9946 (Br79) and 332.9925 (Br81), found 330.9945 and 332.9945.

4.3. Preparation of Biaryls 1a–e

Suzuki-Miyaura Cross-Coupling General Procedure: To a solution of aryl bromide 6 in either toluene:EtOH (3:1 ratio) or toluene:DME:H2O (1:1.3:2.9 ratio) was added boronic acid or derivative 5a–e (1.2–1.5 equiv). Either aq. 2 M K2CO3 (6.0 equiv) or Cs2CO3 (3.5 equiv) was added followed by purging of the reaction mixture with Ar for 10 min. Then, catalytic Pd(dppf)Cl2 (30 mol%) or Pd(PPh3)4 (5–10 mol%) was added with additional purging with Ar for 10 min before allowing the reaction to stir at 85–110 °C for 12–16 h. Then, reactions were allowed to cool to room temperature, concentrated, and extracted with CH2Cl2 (50 mL). The organic layer was dried with Na2SO4, filtered, concentrated, and purified via FCC to afford cross-coupling products 1a–e.
4-Methoxyphenyl Biaryl 1a: General procedure A was followed with aryl bromide 6 (50 mg, 0.16 mmol, 1.0 equiv), toluene:DME:H2O (0.7 mL:0.9 mL:2.0mL), potassium-4-methoxyphenyl-trifluoroborate 5a (46 mg, 0.19 mmol, 1.2 equiv), Cs2CO3 (183 mg, 0.56 mmol, 3.5 equiv), and Pd(PPh3)4 (9 mg, 0.008 mmol, 0.05 equiv) for 16 h at 85 °C. Purification by FCC (hexanes:EtOAc 80:20) delivered 4-methoxyphenyl biaryl 1a as a pale yellow solid (38 mg, 0.11 mmol, 69%): Rf = 0.47 (hexanes:EtOAc 70:30); mp 72–73 °C; 1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 2.3 Hz, 1H), 7.50 (app d, J = 8.8 Hz, 1H), 7.43 (dd, J = 8.4, 2.3 Hz, 1H), 7.02 (d, J = 8.4 Hz, 1H), 6.95 (app d, J = 8.8 Hz, 1H), 6.12 (ddd, J = 9.8, 4.1, 1.8 Hz, 1H), 5.68 (dd, J = 9.8, 2.1 Hz, 1H), 4.85 (br s, 1H), 4.59 (dd, J = 6.0, 4.1 Hz, 1H), 4.41 (dd, J = 9.8, 5.5 Hz, 1H), 3.85 (s, 3H), 3.41 (dd, J = 12.3, 9.8 Hz, 1H), 3.44-3.30 (m, 1H), 2.21 (dd, J = 11.7, 7.9 Hz, 1H), 1.67-1.60 (m, 1H), 1.42 (br s, 1H); 13C{1H} NMR (100 MHz, CDCl3) δ 159.0, 156.4, 135.2, 133.7, 133.2, 127.9(2), 127.8, 127.7, 126.2, 124.9, 117.7, 114.3(2), 80.8, 74.9, 73.5, 69.9, 55.5, 36.7, 34.6; ESI-HRMS calculated for C21H20O4Na [M + Na]+ 359.1259, found 359.1243.
2-Fluoropyridyl Biaryl 1b: General procedure A was followed with aryl bromide 6 (50 mg, 0.16 mmol, 1.0 equiv), toluene:EtOH (3 mL:1 mL), 2-fluoropyridine-4-boronic acid 5b (34 mg, 0.24 mmol, 1.5 equiv), aq. K2CO3 (0.4 mL, 0.98 mmol, 6.0 equiv) and Pd(dppf)Cl2 (36 mg, 0.049 mmol, 0.30 equiv) for 16 h at 110 °C. Purification by FCC (hexanes:EtOAc 80:20 to 60:40) delivered 2-fluoropyridyl biaryl 1b as a white solid (20 mg, 0.06 mmol, 38%): Rf = 0.28 (hexanes:EtOAc 70:30); mp 186–187 °C; 1H NMR (500 MHz, CDCl3) δ 8.22 (app d, J = 5.3 Hz, 1H), 7.87 (app d, J = 2.3 Hz, 1H), 7.53 (app dd, J = 8.5, 2.3 Hz, 1H), 7.38 (app ddd, J = 5.3, 2.0, 1.5 Hz, 1H), 7.11–7.10 (m, 1H), 7.10 (app d, J = 8.5 Hz, 1H), 6.14 (ddd, J = 9.8, 4.1, 1.8 Hz, 1H), 5.68 (dd, J = 9.9, 2.1 Hz, 1H), 4.84–4.81 (m, 1H), 4.60 (dd, J = 6.2, 4.1 Hz, 1H), 4.45 (dd, J = 9.8, 5.4 Hz, 1H), 3.41 (dd, J = 12.4, 9.8 Hz, 1H), 3.41–3.31 (m, 1H), 2.23 (dd, J = 11.6, 7.8 Hz, 1H), 1.67–1.61 (m, 1H), 1.45 (d, J = 4.8 Hz, 1H); 13C{1H} NMR (125 MHz, CDCl3) δ 165.7, 163.8, 158.8, 153.4 (J = 8.3 Hz), 148.0 (J = 15.8 Hz), 133.8, 131.1 (J = 3.2 Hz), 127.9 (J = 14.6 Hz), 127.1, 125.9, 119.2 (J = 3.6 Hz), 118.5, 106.6 (J = 38.0 Hz), 80.6, 75.0, 73.6, 70.1, 36.7, 34.6; ESI-HRMS calculated for C19H17NO3F [M + H]+ 326.1192, found 326.1179.
6-Indole Biaryl 1c: General procedure A was followed with aryl bromide 6 (50 mg, 0.16 mmol, 1.0 equiv), toluene:DME:H2O (0.7 mL:0.9 mL:2.0mL), 6-indoleboronic acid 5c (39 mg, 0.24 mmol, 1.5 equiv), Cs2CO3 (78 mg, 0.56 mmol, 3.5 equiv) and Pd(PPh3)4 (9 mg, 0.008 mmol, 0.05 equiv) for 16 h at 85 °C. Purification by FCC (CH2Cl2:EtOAc 90:10) delivered 6-indole biaryl 1c as a pale yellow-white solid (11 mg, 0.03 mmol, 19%): Rf = 0.67 (CH2Cl2:EtOAc 85:15); mp 70–73 °C; 1H NMR (500 MHz, CDCl3) δ 8.17 (br s, 1H), 7.86 (d, J = 2.3 Hz, 1H), 7.67 (d, J = 8.2 Hz, 1H), 7.57–7.55 (m, 1H), 7.54 (dd, J = 8.5, 2.3 Hz, 1H), 7.37 (dd, J = 8.2, 1.6 Hz, 1H), 7.22 (dd, J = 3.1, 2.3 Hz, 1H), 7.04 (d, J = 8.5 Hz, 1H), 6.56 (app ddd, J = 3.1, 2.0, 0.9 Hz, 1H), 6.12 (ddd, J = 9.9, 4.1, 1.8 Hz, 1H), 5.68 (dd, J = 9.9, 2.1 Hz, 1H), 4.87 (br s, 1H), 4.59 (dd, J = 6.0, 4.1 Hz, 1H), 4.41 (dd, J = 10.0, 5.8 Hz, 1H), 3.43 (dd, J = 12.3, 10.0 Hz, 1H), 3.39-3.29 (m, 1H), 2.22 (dd, J = 11.6, 8.0 Hz, 1H), 1.68–1.60 (m, 1H), 1.49 (d, J = 4.4 Hz, 1H); 13C{1H} NMR (125 MHz, CDCl3) δ 156.4, 136.7, 136.6, 135.0, 133.8, 128.4, 127.8, 127.2, 126.8, 124.85, 124.77, 121.0, 119.7, 117.7, 109.3, 102.7, 80.9, 75.0, 73.6, 70.0, 36.7, 34.7; ESI-HRMS calculated for C22H19NO3Na [M + Na]+ 368.1263, found 368.1250.
Benzothiazole Biaryl 1d: General procedure A was followed with aryl bromide 6 (50 mg, 0.16 mmol, 1.0 equiv), toluene:DME:H2O (0.7 mL:0.9 mL:2.0mL), benzothiazole-5-boronic acid pinacol ester 5d (63 mg, 0.24 mmol, 1.5 equiv), Cs2CO3 (78 mg, 0.56 mmol, 3.5 equiv) and Pd(PPh3)4 (9 mg, 0.008 mmol, 0.05 equiv) for 16 h at 85 °C. Purification by FCC (CH2Cl2:EtOAc 95:5 to 80:20) and (hexanes:EtOAc 70:30) delivered benzothiazole biaryl 1d as a pale yellow solid (40 mg, 0.11 mmol, 69%): Rf = 0.47 (CH2Cl2:EtOAc 85:15); mp 141–142 °C; 1H NMR (500 MHz, CDCl3) δ 9.02 (app s, 1H), 8.32 (app dd, J = 1.8, 0.6 Hz, 1H), 7.99 (app dd, J = 8.4, 0.6 Hz, 1H), 7.91 (app d, J = 2.3 Hz, 1H), 7.68 (app ddd, J = 8.4, 1.8, 0.5 Hz, 1H), 7.57 (app dd, J = 8.5, 2.3 Hz, 1H), 7.09 (app dd, J = 8.5, 0.3 Hz, 1H), 6.13 (ddd, J = 9.8, 4.1, 1.8 Hz, 1H), 5.69 (dd, J = 9.8, 2.1 Hz, 1H), 4.90–4.87 (m, 1H), 4.60 (dd, J = 6.0, 4.1 Hz, 1H), 4.44 (dd, J = 10.2, 5.9 Hz, 1H), 3.44 (dd, J = 12.4, 10.2 Hz, 1H), 3.41–3.33 (m, 1H), 2.23 (dd, J = 11.7, 8.0 Hz, 1H), 1.68–1.62 (m, 1H), 1.53 (d, J = 4.6 Hz, 1H); 13C{1H} NMR (125 MHz, CDCl3) δ 157.1, 154.8, 153.8, 139.3, 134.6, 133.6, 132.1, 128.2, 128.1, 127.1, 125.4, 125.0, 122.0, 121.3, 117.9, 80.8, 74.8, 73.5, 70.0, 36.7, 34.6; ESI-HRMS calculated for C21H17NO3SNa [M + Na]+ 386.0827, found 386.0820.
Pyrimidine Biaryl 1e: General procedure A was followed with aryl bromide 6 (50 mg, 0.16 mmol, 1.0 equiv), toluene:DME:H2O (0.7 mL:0.9 mL:2.0mL), pyrimidine-5-boronic acid 5e (30 mg, 0.24 mmol, 1.5 equiv), Cs2CO3 (78 mg, 0.56 mmol, 3.5 equiv) and Pd(PPh3)4 (9 mg, 0.008 mmol, 0.05 equiv) for 16 h at 85 °C. Purification by FCC (hexanes:EtOAc 80:20 to 60:40) delivered pyrimidine biaryl 1e as a pale yellow solid (20 mg, 0.065 mmol, 40%): Rf = 0.45 (hexanes:EtOAc 50:50); mp 183–184 °C; 1H NMR (500 MHz, CDCl3) δ 9.01 (s, 1H), 8.67 (s, 1H), 7.76 (d, J = 2.3 Hz, 1H), 7.31 (dd, J = 8.4, 2.3 Hz, 1H), 7.07 (d, J = 8.4 Hz, 1H), 6.12 (ddd, J = 9.8, 4.1, 1.8 Hz, 1H), 5.70 (dd, J = 9.8, 2.1 Hz, 1H), 4.83 (br s, 1H), 4.58 (dd, J = 6.1, 4.1 Hz, 1H), 4.48–4.43 (m, 1H), 3.44–3.35 (m, 2H), 2.23 (dd, J = 11.8, 8.0 Hz, 1H), 1.72 (br s, 1H), 1.67–1.59 (m, 1H); 13C{1H} NMR (125 MHz, CDCl3) δ 158.5, 156.8, 154.2(2), 133.8, 133.5, 128.7, 128.5, 127.7, 126.9, 126.8, 118.7, 80.7, 74.6, 73.6, 70.1, 36.7, 34.6; ESI-HRMS calculated for C18H17N2O3 [M + H]+ 309.1239, found 309.1220.

4.4. Biological Methods

Cells and Cell Culturing Methods:Leishmania tarentolae (L. tarentolae) were cultured at 22 °C in the dark in 250 mL CELLTREAT Suspension Culture Flasks (ThermoFisher Scientific, Waltham, MA, USA). Brain heart infusion media (BHI) supplemented with penicillin, streptomycin, and hemin was used for L. tarentolae culturing following the method of Morgenthaler et al. [97]. Axenic Rattus norvegicus C6 glioma cells (ATCC CCL-107) were cultured in FALCON 6-well culture plates using high glucose Dulbecco’s Modified Eagles Medium (incomplete DMEM; Sigma Life Sciences D6429; St. Louis, MO, USA) supplemented with 15% (v/v) horse serum (ATCC; Manassas, VA, USA) and 5% (v/v) heat-treated fetal bovine serum (GIBCO; Waltham, MA, USA) (now designated as complete DMEM) at 37 °C and maintained under a 5% CO2 atmosphere following the method of Vallejo et al. [98]. For experimentation, cells were harvested by trypsinization, following the manufacturer’s recommendations (Sigma Aldrich), and resuspended in complete DMEM. This cell suspension was then added to sterile 96-well cell culture plates (Falcon®) in 100 μL aliquots. MTT viability assay [95] was performed following the method of Mendez et al. [99]. From a homogenous suspension, Leishmania (100 µL per well) were loaded in quadruplicate; for glial cells, the growth medium was removed, replaced with 100 µL per well of incomplete medium diluted 1:10 with saline. Reactions were evaluated at A 595 nm using a BIO-RAD iMark microplate reader. Incubation times were varied depending on stage in the growth curve and number of cells, as the MTT assay is dependent upon NAD(P)H-dependent oxidoreductase enzymes [100]. MTT samples were averaged per condition, corrected for BHI background, and normalized per hour of MTT incubation at room temperature (following the method of Mendez et al. [99]). When applicable, ANOVA followed by Tukey Post Test was used to evaluate statistical differences relative to control cells; a p value < 0.05 is considered significantly different. Number of replicates are indicated in the appropriate graphs and tables.
Evaluation of Compound Effects on L. tarentolae Growth: Equal volumes of early log-phase L. tarentolae were aliquoted into 4.95 mL of BHI medium in separate 25 mL Falcon culture flasks. The 30 mM stock solutions were diluted 1:10 in DMSO for a working stock of 3 Mm. Then, 50 µL of the working stock was added to each flask for a final concentration of 30 µM of compound and 1% DMSO. A no-cell flask, containing BHI and 1% DMSO, was used as the blank and a cell culture containing 1% DMSO was used as the control cells. The MTT assay was performed before compound addition to test baseline cell viability and then every 24 h following additions for 96 h.
Evaluation of Leishmania Secreted Acid Phosphatase (SAP):Leishmania secreted acid phosphatase (SAP) assay (using the method of Mendez et al. [99]) was used to determine enzyme activity from cell-free supernatant as a function of compound incubation. Homogenous samples were taken from culture flasks of varying conditions and stock cultures and centrifuged (10,000 rpm, 60 s, Eppendorf Centrifuge 5415C) in 1.5 mL polypropylene tubes, and then, the supernatant was used as the enzyme source. Per each reaction, supernatant (450 µL) was mixed with 450 µL of sodium acetate buffer (0.5 M, pH 4.5) in a 1.5 mL microcentrifuge tubes and reactions were done in triplicate (following the method of Mendez et al. [44]). One hundred µL of a 5 mg/mL (14.7 mM) solution of para-nitrophenyl phosphate disodium salt hexahydrate (pNPP, Sigma-Aldrich) was added to each tube to start the enzymic reaction. The reaction was stopped ~24 h after it started with the addition of 100 µL of NaOH (10.0 M). SAP enzymic activity produces para-nitrophenol, which is converted to the nitrophenylate anion upon the addition of NaOH, it has an absorbance at 405 nm, and it was evaluated using an Agilent Hewlett Packard 8453 UV-visible spectrophotometer. Samples were averaged per condition for n = 4 replicates, corrected for BHI, and normalized per 24-h incubation time.
Evaluation of Direct Enzymic Effect of Test Compounds on SAP: A stock culture of L. tarentolae in the late stationary phase was centrifuged (3000 rpm, 15 min @ 7 °C, Labnet HERMLE Z 400K centrifuge), and the cell-free supernatant was collected. This standard pool of enzyme was separated into equal volumes and allowed to incubate with each of the 6 compounds at 30 µM or 1% DMSO for 15 min, 18 h, or 46 h before starting the SAP assay.
SAP Enzyme Kinetic Assay using Selected Test Compounds (following the method of Dorsey et al. [28]): A stock culture of L. tarentolae in the late stationary phase, was pelleted, retaining the supernatant. This standard pool of SAP enzyme was separated into equal volumes and allowed to incubate with 30 µM compounds 6, 1c, and 1e. Pre-incubated samples were aliquoted with 13 varying substrate concentrations ranging from 4.5 µM to 1787 µM.
Evaluation of Test Compound Acute Effects on Glial Viability: Test compounds prepared in DMSO and diluted into incomplete DMEM were introduced, at a concentration of 30 µM, when the glial cells in the 96-well plates reached confluency. MTT assays were conducted in incomplete DMEM diluted 1:10 with sterile saline following a two-hour incubation with the compounds.
Effective Dose (ED-50) Study on L. tarentolae: Equal volumes of late log-phase L. tarentolae were aliquoted into separate flasks with compounds 6, 1c, or 1e at 8 varying final concentrations ranging from 3 to 200 µM. MTT assays were performed 24 h and 48 h post-addition of compounds.
Evaluation of Photosensitivity of L. tarentolae in the Presence of Test Compounds: Equal volumes of late log-phase L. tarentolae were aliquoted into separate flasks with 30 µM of compounds 6, 1c, or 1e. Cultures were incubated 1 h in the dark to allow uptake of compounds before exposing to a fluorescent bulb (following the method of Morgenthaler et al. [97]), or a UV bulb for 1 h. Cells kept in the dark were considered the control cells. MTT assays were performed directly after compound addition as well as 2 h, 24 h, and 48 h after light exposure.
Evaluation of production of nitric oxide by Leishmania in the presence of test compounds: Nitric oxide (NO) assay was performed using DAF-FM diacetate (a compound that fluoresces after reaction with nitric oxide; from Millipore Sigma, Darmstadt, Germany) at a final concentration of 20 μM and 1% DMSO in saline. Cells were centrifuged (10,000 rpm, 60 s, Eppendorf Centrifuge 5415C) and resuspended in this DAF-FM diacetate solution for 1 h before re-centrifuging, which was followed by washing the cell pellet with 500 µL saline. Cells were resuspended in a final total volume of saline such that there were a similar number of cells per sample. Prior to imaging, 10 μL of each sample was loaded onto a glass slide within a silicon grease ring and then covered with a cover slip. Sample slides were placed in a BZX-810 Keyence Fluorescent Microscope for imaging using a green fluorescent protein filter (GFP; 470 nm: 525 nm excitation-emission coupling). Images were captured at a 1.5 s exposure time and overlays of fluorescent cells with the brightfield images were produced using the analyzer software. Cells were then counted for number of green fluorescent cells (indicating production of nitric oxide) and number of non-green cells.

Supplementary Materials

The following are available online, Figure S1: 1H NMR (500 MHz) of 7 in CDCl3, Figure S2: 13C NMR (100 MHz) of 7 in CDCl3, Figure S3: 1H NMR (500 MHz) of 6 in CDCl3, Figure S4: 13C NMR (125 MHz) of 6 in CDCl3, Figure S5: 1H NMR (400 MHz) of 1a in CDCl3, Figure S6: 13C NMR (100 MHz) of 1a in CDCl3, Figure S7: 1H NMR (500 MHz) of 1b in CDCl3, Figure S8: 13C NMR (125 MHz) of 1b in CDCl3, Figure S9: 1H NMR (500 MHz) of 1c in CDCl3, Figure S10: 13C NMR (125 MHz) of 1c in CDCl3, Figure S11: 1H NMR (500 MHz) of 1d in CDCl3, Figure S12: 13C NMR (125 MHz) of 1d in CDCl3, Figure S13: 1H NMR (500 MHz) of 1e in CDCl3, Figure S14: 13C NMR (125 MHz) of 1e in CDCl3, Figure S15. Overlay image of 1% DMSO control cell pool, Figure S16. Overlay image of compound 1b incubation, Figure S17. Overlay image of compound 1c incubation, Figure S18. Overlay image of compound 1e incubation, Figure S19. Overlay image of mixed incubation of compounds 1b + 1e, Figure S20. Overlay of mixed incubation of compounds 1c + 1e.

Author Contributions

Conceptualization, M.A.J. and T.A.M.; Data curation, S.S., J.P.G., S.P., C.F.A. and D.C.P.; Funding acquisition, T.A.M.; Investigation, S.S., J.P.G., S.P., C.F.A. and D.C.P.; Project administration, M.A.J. and T.A.M.; Supervision, M.A.J. and T.A.M.; Writing—original draft, M.A.J. and T.A.M.; Writing—review & editing, S.S., J.P.G., S.P., C.F.A., D.C.P., M.A.J. and T.A.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Science Foundation, grant numbers CHE-1565644, CHE-0722385, and CHE-1337497.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Centers for Disease Control and Prevention (CDC). About Leishmaniasis. Available online: https://www.cdc.gov/parasites/leishmaniasis/gen_info/faqs.html (accessed on 17 October 2020).
  2. Burza, S.; Croft, A.I.; Boelaert, M. Leishmaniasis. Lancet 2020, 392, 951–970. [Google Scholar] [CrossRef]
  3. Centers for Disease Control and Prevention (CDC). Epidemiology and Risk Factors. Available online: https://www.cdc.gov/parasites/leishmaniasis/epi.html (accessed on 17 October 2020).
  4. Torres-Guerrero, E.; Quintanilla-Cedillo, M.R.; Ruiz-Esmenjaud, J.; Arenas, R. Leishmaniasis: A review. F1000Research 2017, 6, 750. [Google Scholar] [CrossRef]
  5. Herrera, G.; Barragan, N.; Luna, N.; Martinez, D.; De Martino, F.; Medina, J.; Nino, S.; Paez, L.; Ramirez, A.; Vega, L.; et al. An interactive database of Leishmania species distribution in the Americas. Sci. Data 2020, 7, 110. [Google Scholar] [CrossRef] [Green Version]
  6. Clarke, C.F.; Bradley, K.K.; Wright, J.H.; Glowicz, J. Case Report: Emergence of Autochthonous Cutaneous Leishmaniasis in Northeastern Texas and Southeastern Oklahoma. Am. J. Trop. Med. Hyg. 2013, 88, 157–161. [Google Scholar] [CrossRef]
  7. McHugh, C.P.; Melby, P.C.; LaFon, S.G. Leishmaniasis in Texas: Epidemiology and clinical aspects of human cases. Am. J. Trop. Med. Hyg. 1996, 55, 547–555. [Google Scholar] [CrossRef] [PubMed]
  8. Aronson, N.; Herwaldt, B.L.; Libman, M.; Pearson, R.; Lopez-Velez, R.; Weina, P.; Carvalho, E.M.; Ephros, M.; Jeronimo, S.; Magill, A. Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin. Inf. Dis. 2016, 63, e202–e264. [Google Scholar] [CrossRef] [PubMed]
  9. Centers for Disease Control and Prevention (CDC). Disease. Available online: https://www.cdc.gov/parasites/leishmaniasis/disease.html (accessed on 17 October 2020).
  10. Bekhit, A.A.; El-Agroudy, E.; Helmy, A.; Ibrahim, T.M.; Shavandi, A.; Bekhit, A.E.-D.A. Leishmania treatment and prevention: Natural and synthesized drugs. Eur. J. Med. Chem. 2018, 160, 229–244. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Nagle, A.S.; Khare, S.; Kumar, A.B.; Supek, F.; Buchynskyy, A.; Mathison, C.J.N.; Chennamaneni, N.K.; Pendem, N.; Buckner, F.S.; Gelb, M.H.; et al. Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis. Chem. Rev. 2014, 114, 11305–11347. [Google Scholar] [CrossRef] [Green Version]
  12. Centers for Disease Control and Prevention (CDC). Treatments. Available online: https://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html#tx (accessed on 17 October 2020).
  13. Ratnayake, R.; Covell, D.; Ransom, T.T.; Gustafson, K.R.; Beutler, J.A. Englerin A, a Selective Inhibitor of Renal Cancer Cell Growth, from Phyllanthus engleri. Org. Lett. 2008, 11, 57–60. [Google Scholar] [CrossRef] [Green Version]
  14. Pouwer, R.H.; Richard, J.-A.; Tseng, C.C.; Chen, D.Y.-K. Chemical Synthesis of the Englerins. Chem. Asian J. 2012, 7, 22–35. [Google Scholar] [CrossRef]
  15. Chain, W.J. Synthetic Strategies toward the Guaiane Sesquiterpene Englerin A. Synlett 2011, 2011, 2605–2608. [Google Scholar] [CrossRef]
  16. Nicolaou, K.C.; Kang, Q.; Ng, S.Y.; Chen, D.Y.-K. Total Synthesis of Englerin A. J. Am. Chem. Soc. 2010, 132, 8219–8222. [Google Scholar] [CrossRef] [PubMed]
  17. Sourbier, C.; Scroggins, B.T.; Ratnayake, R.; Prince, T.L.; Lee, S.; Lee, M.-J.; Nagy, P.L.; Lee, Y.H.; Trepel, J.B.; Buetler, J.A.; et al. Englerin A Stimulates PKCθ to Inhibit Insulin Signaling and to Simultaneously Activate HSF1: Pharmacologically Induced Synthetic Lethality. Cancer Cell 2013, 23, 228–237. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  18. Feng, X.; Tran, K.D.; Sanchez, M.A.; Mezewghi, H.A.; Landfear, S.M. Glucose Transporters and Virulence in Leishmania Mexicana. mSphere 2018, 3, e00349-18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Nicolaou, K.C.; Pfefferkorn, J.A.; Roecker, A.J.; Cao, G.-Q.; Barluenga, S.; Mitchell, H.J. Natural Product-like Combinatorial Libraries based on Privileged Structures. 1. General Principles and Solid-Phase Synthesis of Benzopyrans. J. Am. Chem. Soc. 2000, 122, 9939–9953. [Google Scholar] [CrossRef]
  20. Nicolaou, K.C.; Pfefferkorn, J.A.; Roecker, A.J.; Barluenga, S.; Cao, G.-Q.; Affleck, R.L.; Lillig, J.E. Natural Product-like Combinatorial Libraries based on Privileged Structures. 2. Construction of a 10,000-Membered Benzopyran Library by Directed Split-and-Pool Chemistry Using NanoKans and Optical Encoding. J. Am. Chem. Soc. 2000, 122, 9954–9967. [Google Scholar] [CrossRef]
  21. Nicolaou, K.C.; Pfefferkorn, J.A.; Barluenga, S.; Mitchell, H.J.; Roecker, A.J.; Cao, G.-Q. Natural Product-like Combinatorial Libraries based on Privileged Structures. 3. The “Libraries from Libraries” Principle for Diversity Enhancement of Benzopyran Libraries. J. Am. Chem. Soc. 2020, 122, 9968–9976. [Google Scholar] [CrossRef]
  22. Duarte, C.D.; Barreiro, E.J.; Fraga, C.A.M. Privileged Structures: A Useful Concept for the Rational Design of New Lead Candidates. Mini Rev. Med. Chem. 2007, 7, 1108–1119. [Google Scholar] [CrossRef]
  23. Foroumadi, A.; Emami, S.; Sorkhi, M.; Nakhjiri, M.; Nazarian, Z.; Heydari, S.; Ardestani, S.K.; Poorrajab, F.; Shafiee, A. Chromene-Based Synthetic Chalcones as Potent Antileshmanial Agents: Synthesis and Biological Activity. Chem. Biol. Drug Des. 2010, 75, 590–596. [Google Scholar] [CrossRef]
  24. Lopez, S.P.; Yepes, L.M.; Perez-Castillo, Y.; Robledo, S.M.; de Sousa, D.P. Alkyl and Aryl Derivatives Based on p-Coumaric Acid Modification and Inhibitory Action against Leishmania braziliensis and Plasmodium falciparum. Molecules 2020, 25, 3178. [Google Scholar] [CrossRef]
  25. Klatt, S.; Simpson, L.; Maslov, D.A.; Konthur, Z. Leishmania tarentolae: Taxonomic classification and its application as a promising biotechnological expression host. PLoS Negl. Trop. Dis. 2019, 13, e0007424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Taylor, V.M.; Muñoz, D.L.; Cedeño, D.L.; Vélez, I.D.; Jones, M.A.; Robledo, S.M. Leishmania tarentolae: Utility as an in vitro model for screening of antileishmanial agents. Exp. Parasitol. 2010, 126, 471–475. [Google Scholar] [CrossRef] [PubMed]
  27. Belzowski, A.J.; Hooker, J.D.; Young, A.M.; Cedeño, D.L.; Peters, S.J.; Lash, T.D.; Jones, M.A. Nitric Oxide Production within Leishmania tarentolae Axenic Promastigotes and Amastigotes Is Induced by Carbaporphyrin Ketals. JSM Trop. Med. Res. 2016, 1, 1004. [Google Scholar]
  28. Dorsey, B.M.; Cass, C.L.; Cedeño, D.L.; Vallejo, R.; Jones, M.A. Effects of Specific Electric Field Stimulation on the Kinetics of Secreted Acid Phosphatases from Leishmania tarentolae and Implications for Therapy. Pathogens 2018, 7, 77. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. Kunz, H.; Mullen, K. Natural Products and Materials Chemistry-Separated Forever? J. Am. Chem. Soc. 2013, 135, 8764–8769. [Google Scholar] [CrossRef] [PubMed]
  30. Kesavan, S.; Marcaurelle, L.A. Translational synthetic chemistry. Nat. Chem. Biol. 2013, 9, 210–213. [Google Scholar] [CrossRef]
  31. Hoffmann, R.W. Natural Products Synthesis: Changes over Time. Angew. Chem. Int. Ed. 2013, 52, 123–130. [Google Scholar] [CrossRef]
  32. Mohr, J.T.; Krout, M.R.; Stoltz, B.M. Natural products as inspiration for the development of asymmetric catalysis. Nature 2008, 455, 323–332. [Google Scholar] [CrossRef] [Green Version]
  33. Koehn, F.E.; Carter, G.T. The Evolving Role of Natural Products in Drug Discovery. Nat. Rev. Drug Discov. 2005, 4, 206–220. [Google Scholar] [CrossRef]
  34. Butler, M. The Role of Natural Product Chemistry in Drug Discovery. J. Nat. Prod. 2004, 67, 2141–2153. [Google Scholar] [CrossRef]
  35. Lesney, M.S. Nature’s Pharmaceuticals. Today’s Chemist at Work, July 2004; 26–32. Available online: http://www.scripps.edu/baran/pdfExtras/bothernp.pdf(accessed on 17 October 2020).
  36. MacCoss, M.; Baillie, T.A. Organic Chemistry in Drug Discovery. Science 2004, 303, 1810–1813. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Alvim-Gaston, M.; Grese, T.; Mahoui, A.; Palkowitz, A.D.; Pineiro-Nunez, M.; Watson, I. Open-Innovation Drug Discovery (OIDD): A Potential Path to Novel Therapeutic Chemical Space. Curr. Top. Med. Chem. 2014, 14, 294–303. [Google Scholar] [CrossRef] [PubMed]
  38. O’Conner, C.J.; Beckmann, H.S.G.; Spring, D.R. Diversity-oriented synthesis: Producing chemical tools for dissecting biology. Chem. Soc. Rev. 2012, 41, 4444–4456. [Google Scholar] [CrossRef] [PubMed]
  39. Anagnostaki, E.E.; Zografos, A.L. Common synthetic scaffolds in the synthesis of structurally diverse natural products. Chem. Soc. Rev. 2012, 41, 5613–5625. [Google Scholar] [CrossRef]
  40. Dandapani, S.; Marcaurelle, L.A. Accessing new chemical space for ‘undruggable’ targets. Nat. Chem. Biol. 2010, 6, 861–863. [Google Scholar] [CrossRef]
  41. Spandl, R.J.; Diaz-Gavilan, M.; O’Connell, K.M.G.; Thomas, G.L.; Spring, D.R. Diversity-Oriented Synthesis. Chem. Rec. 2008, 8, 129–142. [Google Scholar] [CrossRef]
  42. Tan, D.S. Diversity-oriented synthesis: Exploring the intersections between chemistry and biology. Nat. Chem. Biol. 2005, 1, 74–84. [Google Scholar] [CrossRef]
  43. Ulaczyk-Lesanko, A.; Hall, D.G. Wanted: New multicomponent reactions for generating libraries of polycyclic natural products. Curr. Opin. Chem. Biol. 2005, 9, 266–276. [Google Scholar] [CrossRef]
  44. Burke, M.; Schreiber, S.L. A Planning Strategy for Diversity-Oriented Synthesis. Angew. Chem. Int. Ed. 2004, 43, 46–58. [Google Scholar] [CrossRef]
  45. Schreiber, S. Target-Oriented and Diversity-Oriented Organic Synthesis in Drug Discovery. Science 2000, 287, 1964–1969. [Google Scholar] [CrossRef] [Green Version]
  46. Dakas, P.-Y.; Parga, J.A.; Hoing, S.; Scholer, H.R.; Sterneckert, J.; Kumar, K.; Waldmann, H. Discovery of Neuritogenic Compound Classes Inspired by Natural Products. Angew. Chem. Int. Ed. 2013, 52, 9576–9581. [Google Scholar] [CrossRef] [PubMed]
  47. Voigt, T.; Gerding-Reimers, C.; Tran, T.T.N.; Bergmann, S.; Lachance, H.; Scholermann, B.; Brockmeyer, A.; Janning, P.; Ziegler, S.; Waldmann, H. A Natural Product Inspired Tetrahydropyran Collection Yields Mitosis Modulators that Synergistically Target CSE1L and Tubulin. Angew. Chem. Int. Ed. 2012, 51, 410–414. [Google Scholar]
  48. Heidebrecht, R.W., Jr.; Mulrooney, C.; Austin, C.P.; Barker, R.H., Jr.; Beaudoin, J.A.; Cheng, K.C.-C.; Comer, E.; Dandapani, S.; Dick, J.; Duvall, J.R.; et al. Diversity-Oriented Synthesis Yields a Novel Lead for the Treatment of Malaria. ACS Med. Chem. Lett. 2012, 3, 112–117. [Google Scholar] [CrossRef] [PubMed]
  49. Smith, A.B., III; Kim, W.-S. Diversity-oriented synthesis leads to an effective class of bifunctional linchpins uniting anion relay chemistry (ARC) with benzyne reactivity. Proc. Natl. Acad. Sci. USA 2011, 108, 6787–6792. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  50. Morton, D.; Leach, S.; Cordier, C.; Warriner, S.; Nelson, A. Synthesis of Natural-Product-Like Molecules with Eighty Distinct Scaffolds. Angew. Chem. Int. Ed. 2009, 48, 104–109. [Google Scholar] [CrossRef]
  51. Itami, K.; Kamei, T.; Yoshida, J. Diversity-Oriented Synthesis of Tamifoxen-type Tetrasubstituted Olefins. J. Am. Chem. Soc. 2003, 125, 14670–14671. [Google Scholar] [CrossRef]
  52. Cordier, C.; Morton, D.; Murrison, S.; Nelson, A.; O’Leary-Steele, C. Natural products as an inspiration in the diversity-oriented synthesis of bioactive compound libraries. Nat. Prod. Rep. 2008, 25, 719–737. [Google Scholar] [CrossRef] [Green Version]
  53. Nishiwaki, N. Methods and Applications of Cycloaddition Reactions in Organic Synthesis; Wiley-VCH: Weinheim, Germany, 2014. [Google Scholar]
  54. Kobayashi, S.; Jørgensen, K.A. Cycloaddition Reactions in Organic Chemistry; Wiley-VCH: Weinheim, Germany, 2002. [Google Scholar]
  55. Carruthers, W. Cycloaddition Reactions in Organic Chemistry, Volume 8 (Tetrahedron Organic Chemistry); Pergamon: Oxford, UK, 1990. [Google Scholar]
  56. Diels, O.; Alder, K. Synthesen in der hydroaromatischen Reihe. Justus Liebigs Ann. Chem. 1928, 460, 98–122. [Google Scholar] [CrossRef]
  57. Nicolaou, K.C.; Snyder, S.A.; Montagnon, T.; Vassilikogiannakis, G. The Diels-Alder Reaction in Total Synthesis. Angew. Chem. Int. Ed. 2002, 41, 1668–1698. [Google Scholar] [CrossRef]
  58. Corey, E.J. Catalytic Enantioselective Diels-Alder Reactions: Methods, Mechanistic Fundamentals, Pathways, and Applications. Angew. Chem. Int. Ed. 2002, 41, 1650–1667. [Google Scholar] [CrossRef]
  59. Pellissier, H. Recent Developments in the [5+2] Cycloaddition. Adv. Synth. Catal. 2018, 360, 1551–1583. [Google Scholar] [CrossRef]
  60. Pellissier, H. Recent Developments in the [5+2] Cycloaddition. Adv. Synth. Catal. 2011, 353, 189–218. [Google Scholar] [CrossRef]
  61. Nakata, T. Total Synthesis of Marine Polycyclic Ethers. Chem. Rev. 2005, 105, 4314–4317. [Google Scholar] [CrossRef]
  62. Bejcek, L.P.; Murelli, R.P. Oxidopyrylium [5+2] cycloaddition chemistry: Historical Perspective and recent advances (2008–2018). Tetrahedron 2018, 74, 2501–2521. [Google Scholar] [CrossRef] [PubMed]
  63. Singh, V.; Murali Krishna, U.; Trivedi, G.K. Cycloaddition of oxidopyrylium species in organic synthesis. Tetrahedron 2008, 64, 3405–3428. [Google Scholar] [CrossRef]
  64. Mascareñas, J.L. The [5+2] Cycloaddition Chemistry of β-Alkoxy-γ-pyrones. Adv. Cycloaddit. 1999, 6, 1–54. [Google Scholar]
  65. Min, L.; Liu, X.; Li, C.-C. Total Synthesis of Natural Products with Bridged Bicyclo[m.n.1] Ring Systems via Type II [5 + 2] Cycloaddition. Acc. Chem. Res. 2020, 53, 703–718. [Google Scholar] [CrossRef]
  66. Gao, K.; Zhang, Y.-G.; Wang, Z.; Ding, H. Recent development on the [5+2] cycloadditions and their application in natural product synthesis. Chem. Commun. 2019, 55, 1859–1878. [Google Scholar] [CrossRef]
  67. Liu, X.; Hu, Y.J.; Fan, J.H.; Zhao, J.; Li, S.; Li, C.C. Recent synthetic studies toward natural products via [5+2] cycloaddition reactions. Org. Chem. Front. 2018, 5, 1217–1228. [Google Scholar] [CrossRef]
  68. Ylijoki, K.E.O.; Stryker, J.M. [5+2] Cycloaddition Reactions in Organic and Natural Product Synthesis. Chem. Rev. 2013, 113, 2244–2266. [Google Scholar] [CrossRef]
  69. Nguyen, T.V.; Hartmann, J.M.; Enders, D. Recent Synthetic Strategies to Access Seven-Membered Carbocycles in Natural Product Synthesis. Synthesis 2013, 45, 845–873. [Google Scholar] [CrossRef]
  70. Battiste, M.A.; Pelphrey, P.M.; Wright, D.L. The Cycloaddition Strategy for the Synthesis of Natural Products Containing Carbocyclic Seven-Membered Rings. Chem. Eur. J. 2006, 12, 3438–3447. [Google Scholar] [CrossRef] [PubMed]
  71. Wang, J.; Soisson, S.M.; Young, K.; Shoop, W.; Kodali, S.; Galgoci, A.; Painter, R.; Parthasarathy, G.; Tang, Y.S.; Cummings, R.; et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 2006, 441, 358–361. [Google Scholar] [CrossRef] [PubMed]
  72. Zhang, C.; Ondeyka, J.; Herath, K.; Jayasuriya, H.; Guan, Z.; Zink, D.L.; Dietrich, L.; Burgess, B.; Ha, S.N.; Wang, J.; et al. Platensimycin and Platencin Congeners from Streptomyces platensis. J. Nat. Prod. 2011, 74, 329–340. [Google Scholar] [CrossRef] [PubMed]
  73. Aoki, S.; Watanabe, Y.; Sanagawa, M.; Setiawan, A.; Kotoku, N.; Kobayashi, M. Cortistatins A, B, C, and D, Anti-angiogenic Steroidal Alkaloids, from the Marine Sponge Corticium simplex. J. Am. Chem. Soc. 2006, 128, 3148–3149. [Google Scholar] [CrossRef]
  74. Chen, D.Y.-K.; Tseng, C.C. Chemistry of the cortistatins—A novel class of anti-angiogenic agents. Org. Biomol. Chem. 2010, 8, 2900–2911. [Google Scholar] [CrossRef]
  75. Li, Y.; Pattenden, G. Perspectives on the structural and biosynthetic interrelationships between oxygenated furanocembranoids and their polycyclic congeners found in corals. Nat. Prod. Rep. 2011, 28, 1269–1310. [Google Scholar] [CrossRef]
  76. Tang, B.; Bray, C.D.; Pattenden, G. Total synthesis of (+)-intricarene using a biogenetically patterned pathway from (-)-bipinnatin J, involving a novel transannular [5+2] (1,3-dipolar) cycloaddition. Org. Biomol. Chem. 2009, 7, 4448–4457. [Google Scholar] [CrossRef]
  77. Roethle, P.A.; Hernandez, P.T.; Trauner, D. Exploring Biosynthetic Relationships among Furanocembranoids: Synthesis of (−)-Bipinnatin J, (+)-Intricarene, (+)-Rubifolide, and (+)-Isoepilophodione, B. Org. Lett. 2006, 8, 5901–5904. [Google Scholar] [CrossRef]
  78. Rokey, S.N.; Simanis, J.A.; Law, C.M.; Pohani, S.; Behrends, S.W.; Bulandr, J.J.; Ferrence, G.M.; Goodell, J.R.; Mitchell, T.A. Intramolecular asymmetric oxidopyrylium-based [5 + 2] cycloadditions. Tetrahedron Lett. 2020, 61, 152377. [Google Scholar] [CrossRef]
  79. Grabowski, J.P.; Ferrence, G.M.; Mitchell, T.A. Efforts toward the total synthesis of (±)-toxicodenane A utilizing an oxidopyrylium-based [5+2] cycloaddition of a silicon-tethered BOC-pyranone. Tetrahedron Lett. 2020, 61, 152324. [Google Scholar] [CrossRef]
  80. Bulandr, J.J.; Grabowski, J.P.; Law, C.M.; Shaw, J.L.; Goodell, J.R.; Mitchell, T.A. Investigation of Transfer Group, Tether Proximity, and Alkene Substitution for Intramolecular Silyloxypyrone-Based [5 + 2] Cycloadditions. J. Org. Chem. 2019, 84, 10306–10320. [Google Scholar] [CrossRef] [PubMed]
  81. Kaufman, R.H.; Law, C.M.; Simanis, J.A.; Woodall, E.L.; Zwick, C.R., III; Wedler, H.B.; Wendelboe, P.; Hamaker, C.G.; Goodell, J.R.; Tantillo, D.J.; et al. Oxidopyrylium-Alkene [5 + 2] Cycloaddition Conjugate Addition Cascade (C3) Sequences: Scope, Limitation, and Computational Investigations. J. Org. Chem. 2018, 83, 9818–9838. [Google Scholar] [CrossRef] [PubMed]
  82. Simanis, J.A.; Zwick III, C.R.; Woodall, E.L.; Goodell, J.R.; Mitchell, T.A. Further Investigation of Pyranone Activation. Heterocycles 2015, 91, 149–156. [Google Scholar]
  83. Simanis, J.A.; Law, C.M.; Woodall, E.L.; Hamaker, C.G.; Goodell, J.R.; Mitchell, T.A. Investigation of oxidopyrylium-alkene [5+2] cycloaddition conjugate addition cascade (C3) sequences. Chem. Commun. 2014, 50, 9130–9133. [Google Scholar] [CrossRef] [PubMed]
  84. Woodall, E.L.; Simanis, J.A.; Hamaker, C.G.; Goodell, J.R.; Mitchell, T.A. Unique Reactivity of anti- and syn-Acetoxypyranones en Route to Oxidopyrylium Intermediates Leading to a Cascade Process. Org. Lett. 2013, 15, 3270–3273. [Google Scholar] [CrossRef]
  85. Ji, Y.; Benkovics, T.; Beutner, G.L.; Sfouggatakis, C.; Eastgate, M.D.; Blackmond, D.G. Mechanistic Insights into the Vanadium-Catalyzed Achmatowicz Rearrangement of Furfurol. J. Org. Chem. 2015, 80, 1696–1702. [Google Scholar] [CrossRef]
  86. Georgiadis, M.P.; Albizati, K.F.; Georgiadis, T.M. Oxidative Rearrangement of Furylcarbinols to 6-Hydroxy-2H-Pyran-3(6H)-ones, A Useful Synthon for the Preparation of a Variety of Heterocyclic Compounds. A Review. Org. Prep. Proc. Int. 1992, 24, 95–118. [Google Scholar] [CrossRef]
  87. Achmatowicz, O.; Szechner, P.B.B.; Zwierzchowska, Z.; Zamojski, A. Synthesis of Methyl 2,3-Dideoxy-DL-alk-2-enonpyranosides from Furan Compounds. Tetrahedron 1971, 27, 1973–1996. [Google Scholar] [CrossRef]
  88. Ciufolini, M.A.; Hermann, C.Y.W.; Dong, Q.; Shimizu, T.; Swaminathan, S.; Xi, N. Nitrogen Heterocycles from Furans: The Aza-Achmatowicz Reaction. Synlett 1998, 1998, 105–114. [Google Scholar] [CrossRef]
  89. Torborg, C.; Beller, M. Recent Applications of Palladium-Catalyzed Cross-Coupling Reactions in the Pharmaceutical, Agrochemical, and Fine Chemical Industries. Adv. Synth. Cat. 2009, 351, 3027–3043. [Google Scholar] [CrossRef]
  90. Sasaki, M.; Fuwa, H. Total Synthesis of Polycyclic Ether Natural Products Based on Suzuki-Miyaura Cross-Coupling. Synlett 2004, 2004, 1851–1874. [Google Scholar] [CrossRef]
  91. Vitaku, E.; Smith, D.T.; Njardarson, J.T. Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals. J. Med. Chem. 2014, 57, 10257–10274. [Google Scholar] [CrossRef] [PubMed]
  92. Luche, J.L. Lanthanides in organic chemistry. 1. Selective 1,2-reductions of conjugated ketones. J. Am. Chem. Soc. 1978, 100, 2226–2227. [Google Scholar] [CrossRef]
  93. Baell, J.; Walters, M.A. Chemical con artists foil drug discovery. Nature 2014, 514, 481–483. [Google Scholar] [CrossRef] [PubMed]
  94. Calder, E.D.D.; Sharif, S.A.I.; McGonagle, F.I.; Sutherland, A. One-Pot Synthesis of 5-Amino-2,5-dihydro-1-benzoxepines: Access to Pharmacologically Active Heterocyclic Scaffolds. J. Org. Chem. 2015, 80, 4683–4696. [Google Scholar] [CrossRef] [PubMed]
  95. Mosmann, T. Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays. J. Immunol. Methods 1983, 65, 55–63. [Google Scholar] [CrossRef]
  96. Huffman, S.E.; Yawson, G.K.; Fisher, S.S.; Bothwell, P.J.; Platt, D.C.; Jones, M.A.; Hamaker, C.G.; Webb, M.I. Ruthenium(III) Complexes Containing Thiazole-Based Ligands That Modulate Amyloid-β Aggregation. Metallomics 2020, 12, 491–503. [Google Scholar] [CrossRef]
  97. Morgenthaler, J.B.; Peters, S.J.; Cedeño, D.L.; Constantino, M.H.; Edwards, K.A.; Kamowski, E.M.; Passini, J.C.; Butkus, B.E.; Young, A.M.; Lash, T.D.; et al. Carbaporphyrin ketals as potential agents for a new photodynamic therapy treatment of leishmaniasis. Biorg. Med. Chem. 2008, 14, 7033–7038. [Google Scholar] [CrossRef]
  98. Vallejo, R.; Platt, D.C.; Rink, J.A.; Cass, C.; Eichenberg, K.; Jones, M.A.; Kelley, C.A.; Gupta, A.; Vallejo, A.; Smith, W.J.; et al. Electrical Stimulation of C6 Glioma Cells in vitro Differentially Modulates Gene Expression Related to Chronic Pain Pathways. Brain Sci. 2019, 9, 303. [Google Scholar] [CrossRef] [Green Version]
  99. Mendez, R.S.; Dorsey, B.M.; McLauchlan, C.C.; Beio, M.; Turner, T.L.; Nguyen, V.H.; Su, A.; Beynon, W.; Friesen, J.A.; Jones, M.A. Vanadium Complexes Are in vitro Inhibitors of Leishmania Secreted Acid Phosphatases. Int. J. Chem. 2014, 6, 35–49. [Google Scholar] [CrossRef] [Green Version]
  100. Stockert, J.C.; Horobin, R.W.; Colombo, L.L.; Blázquez-Castro, A. Tetrazolium salts and formazan products in Cell Biology: Viability assessment, fluorescence imaging, and labeling perspectives. Acta Histochem. 2018, 120, 159–167. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Sample Availability: Samples of the compounds are available from the authors.
Molecules 25 05461 g001 550
Figure 1. Hybrid polycyclic ether-benzopyran (1).
Figure 1. Hybrid polycyclic ether-benzopyran (1).
Molecules 25 05461 g001
Molecules 25 05461 g002 550
Figure 2. Diels–Alder [4+2] cycloaddition versus oxidopyrylium-alkene [5+2] cycloaddition.
Figure 2. Diels–Alder [4+2] cycloaddition versus oxidopyrylium-alkene [5+2] cycloaddition.
Molecules 25 05461 g002
Molecules 25 05461 sch001 550
Scheme 1. Previous synthesis of a polycyclic ether-benzopyran 3.
Scheme 1. Previous synthesis of a polycyclic ether-benzopyran 3.
Molecules 25 05461 sch001
Molecules 25 05461 sch002 550
Scheme 2. Proposed Suzuki-Miyaura pathway for the construction of ether-benzopyran analogues 1.
Scheme 2. Proposed Suzuki-Miyaura pathway for the construction of ether-benzopyran analogues 1.
Molecules 25 05461 sch002
Molecules 25 05461 sch003 550
Scheme 3. Synthesis of Suzuki-Miyaura cross-coupling partner 6.
Scheme 3. Synthesis of Suzuki-Miyaura cross-coupling partner 6.
Molecules 25 05461 sch003
Molecules 25 05461 g003 550
Figure 3. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) absorbance values from cells exposed to a single dose of 30 µM polycyclic ether-benzopyrans in DMSO were obtained at each interval (0 h and every 24 h subsequently). Values are the mean for n = 4 replicates and all SD were smaller than 2% of the mean. DMSO cells are considered to be the appropriate control.
Figure 3. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) absorbance values from cells exposed to a single dose of 30 µM polycyclic ether-benzopyrans in DMSO were obtained at each interval (0 h and every 24 h subsequently). Values are the mean for n = 4 replicates and all SD were smaller than 2% of the mean. DMSO cells are considered to be the appropriate control.
Molecules 25 05461 g003
Molecules 25 05461 g004 550
Figure 4. MTT values at 24 h intervals post addition of a single dose of a polycyclic ether-benzopyran. The compounds (30 µM) were added directly after first reading. Arrow indicates time that cells were given fresh medium with no added compound (recovery phase). Values are the mean values from n = 4 replicates.
Figure 4. MTT values at 24 h intervals post addition of a single dose of a polycyclic ether-benzopyran. The compounds (30 µM) were added directly after first reading. Arrow indicates time that cells were given fresh medium with no added compound (recovery phase). Values are the mean values from n = 4 replicates.
Molecules 25 05461 g004
Molecules 25 05461 g005 550
Figure 5. Absorbance (A 405 nm) after 24 h incubation with pNPP. Values are mean ± SD for n = 4 replicates.
Figure 5. Absorbance (A 405 nm) after 24 h incubation with pNPP. Values are mean ± SD for n = 4 replicates.
Molecules 25 05461 g005
Molecules 25 05461 g006 550
Figure 6. Normalized secreted acid phosphatase (SAP) assay absorbance to MTT absorbance per condition.
Figure 6. Normalized secreted acid phosphatase (SAP) assay absorbance to MTT absorbance per condition.
Molecules 25 05461 g006
Molecules 25 05461 g007 550
Figure 7. Absorbance values (A 405 nm) resulting from differing pre-incubation with polycyclic ether-benzopyrans. Values are the mean ± SD for n = 4 replicates. Blue: 15 min; orange: 18 h; gray: 46 h.
Figure 7. Absorbance values (A 405 nm) resulting from differing pre-incubation with polycyclic ether-benzopyrans. Values are the mean ± SD for n = 4 replicates. Blue: 15 min; orange: 18 h; gray: 46 h.
Molecules 25 05461 g007
Molecules 25 05461 g008 550
Figure 8. The dose-response curve at 24 and 48 h after a single addition of test compound 1e at concentrations ranging from 4.5 to 200 µM.
Figure 8. The dose-response curve at 24 and 48 h after a single addition of test compound 1e at concentrations ranging from 4.5 to 200 µM.
Molecules 25 05461 g008
Table
Table 1. Suzuki-Miyaura cross-coupling with aryl bromide 6.
Table 1. Suzuki-Miyaura cross-coupling with aryl bromide 6.
Molecules 25 05461 i001
EntryAr-B (5)% Yield (1) a
1 Molecules 25 05461 i00269 (1a)
2 Molecules 25 05461 i00338 (1b)
3 Molecules 25 05461 i00419 (1c)
4 Molecules 25 05461 i00569 (1d)
5 Molecules 25 05461 i00640 (1e)
a Isolated yield. b 1.2 equiv. of Ar-B 5a was utilized. c Alternative conditions were utilized: Pd(dppf)Cl2 (30 mol %), aq. K2CO3 (6.0 equiv) in tol:EtOH (3:1) at 110 °C.
Table
Table 2. Slopes of growth phase curve (0–72 h) and recovery phase curve (96–144 h).
Table 2. Slopes of growth phase curve (0–72 h) and recovery phase curve (96–144 h).
Compound(s) Added
Condition1% DMSO61a1b1c1d1e1b/1e1c/1e
Growth phase
(AU/hr)		0.0130.0130.00710.0120.00420.00890.0130.0120.0023
Recovery phase
(AU/hr)		0.0170.0180.0120.0160.00590.0140.0160.0160.0042
Recovery/Growth Phase Ratio1.301.371.731.301.431.551.261.371.85
Table
Table 3. Calculated SAP KM and Vmax (from Lineweaver-Burk Plots) after 24-h incubation.
Table 3. Calculated SAP KM and Vmax (from Lineweaver-Burk Plots) after 24-h incubation.
61c1eDMSO Control
KM (µM)386421364396
Vmax (A 405 nm /24 hr)1.071.151.061.08
Table
Table 4. Cell counts for microscopic images of DAF-FM diacetate incubated L. tarentolae and calculated percent of cells able to express nitric oxide (green).
Table 4. Cell counts for microscopic images of DAF-FM diacetate incubated L. tarentolae and calculated percent of cells able to express nitric oxide (green).
Compound(s) Added
Cell counts1% DMSO61a1b1c1d1e1b +1e1c +1e
cells green4883444232275254385669282
cells not green248494674669850703315323334
Total cells counted736838109789613751141371392616
% total green66.341.138.625.338.238.415.117.6445.8
Table
Table 5. Glial cell MTT average absorbances relative to 1% DMSO cell control (n = 4).
Table 5. Glial cell MTT average absorbances relative to 1% DMSO cell control (n = 4).
61a1b1c1d1eDMSO Control
% DMSO Control95.4129.6114.8116.994.497.1100
Table
Table 6. Calculated ED-50 concentration for 1c and 1e at 24 and 48 h after addition.
Table 6. Calculated ED-50 concentration for 1c and 1e at 24 and 48 h after addition.
Time after Addition6 ED-50
(µM)		1c ED-50 (µM)1e ED-50 (µM)
24 h>20072.423.1
48 h>20024.931.5
Table
Table 7. MTT absorbances relative to 1% DMSO cell control, 6, 1c, or 1e at 2, 24, and 48 h post addition. D = DMSO, N = normal conditions (dark), F = fluorescent bulb, UV = ultraviolet bulb.
Table 7. MTT absorbances relative to 1% DMSO cell control, 6, 1c, or 1e at 2, 24, and 48 h post addition. D = DMSO, N = normal conditions (dark), F = fluorescent bulb, UV = ultraviolet bulb.
Time after AdditionD-ND-FD-UV6-N6-F6-UV1c-N1c-F1c-UV1e-N1e-F1e-UV
2 h10099.799.899.2101.5102.7104.9102.798.298.295.095.8
24 h10091.196.698.0103.3105.173.875.070.998.097.194.9
48 h100104.0100.699.6105.5100.364.067.661.699.3100.0100.1
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Singh, S.; Grabowski, J.P.; Pohani, S.; Apuzzo, C.F.; Platt, D.C.; Jones, M.A.; Mitchell, T.A. Synthesis of Polycyclic Ether-Benzopyrans and In Vitro Inhibitory Activity against Leishmania tarentolae. Molecules 2020, 25, 5461. https://doi.org/10.3390/molecules25225461

AMA Style

Singh S, Grabowski JP, Pohani S, Apuzzo CF, Platt DC, Jones MA, Mitchell TA. Synthesis of Polycyclic Ether-Benzopyrans and In Vitro Inhibitory Activity against Leishmania tarentolae. Molecules. 2020; 25(22):5461. https://doi.org/10.3390/molecules25225461

Chicago/Turabian Style

Singh, Sarita, Jacob P. Grabowski, Shilpa Pohani, C. Fiore Apuzzo, David C. Platt, Marjorie A. Jones, and T. Andrew Mitchell. 2020. "Synthesis of Polycyclic Ether-Benzopyrans and In Vitro Inhibitory Activity against Leishmania tarentolae" Molecules 25, no. 22: 5461. https://doi.org/10.3390/molecules25225461

Article Metrics

Back to TopTop